The report outlines five recommendations and urges authorities and organizations for older people make a concerted effort to the vulnerability of older people by improving their ability to lower to cope with future climate change impacts, he appeals to government .
cancer and other chronic diseases that around the world around the world, can wreak havoc on entire families run, he said, If the cancer not given higher priority by specific global efforts to strengthen health systems in low. Might income and middle-income countries face even more problems as the number of cancer cases increases. More and more and and needlessly from cancer, with devastating social and economic consequences for households, communities and countries alike. Cancer is a major obstacle for the socio-economic development socio-economic development in low-income and economically emerging nations. ..BSD Medical Corporation, a Russell Microcap member of, produced precision-guided implement RF and microwave heat therapy systems for treating cancer and other illnesses or medical terms uses. March 2006 BSD the FDA is a pre-market application of used in to BSD 2000 for certain treatments having radiotherapy. For further information on BSD Medical and its technologies please visit the BSD website at.
And 32nd in that the Phase II conducted which research Munich, Germany with the BSD 2000 cancers therapeutic system showed improvement of patients with pancreatic cancer: – BSD Medical Corp. BSD Medical BSD – 2000 May Hope friend For pancreatic cancer patients provide Even in the worst stage of the disease. When 12 patients advanced or metastatic pancreatic Krebs that was already in the current first-line with chemotherapy had failed chemo in combination with hyperthermia therapy by the BSD -2000 a second-line therapy made available, which event 1 year where free survival was 32 percent. Use advanced or metastatic pancreatic Krebs patients receiving the Recent standard therapy different results, however, appears about his 18 percent the survival rate at one year, what is expected. Only approximately half the patients in of the 25 patients period II clinical trial are currently treated and rated but data this way wide are promising..